


TECH CENTER 1800/2800
RECEIVED

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-355001	Application No. 10/058,630
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Michael L. Camilleri et al	
		Filing Date January 28, 2002	Group Art Unit 1645



Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
SH	AA	5,552,308	09/03/96	Hoffman et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
SH	AC	GenBank Accession No. X76753
SH	AD	Balfour et al., "Alosetron," <u>Drugs</u> , 2000, 59(3):511-518, 519-520
SH	AE	Camilleri et al., "Towards a Less Costly but Accurate Test of Gastric Emptying and Small Bowel Transit," <u>Dig. Dis. Sci.</u> , 1991, 36(5):609-615
SH	AF	Camilleri and Zinsmeister, "Towards a Relatively Inexpensive, Noninvasive, Accurate Test for Colonic Motility Disorders," <u>Gastroenterology</u> , 1992, 103:36-42
SH	AG	Camilleri et al., "Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT ₃ receptor antagonist," <u>Aliment Pharmacol. Ther.</u> , 1999, 13:1149-1159
SH	AH	Camilleri, "Pharmacology and clinical experience with alosetron," <u>Exp. Opin. Invest. Drugs</u> , 2000, 9(1):147-159
SH	AI	Camilleri et al., "Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial," <u>Lancet</u> , 2000, 355:1035-1040
SH	AJ	Cavallini et al., "An association study between 5-HTTLPR polymorphism, COMT polymorphism, and Tourette's syndrome," <u>Psychiatry Res.</u> , 2000, 97:93-100
SH	AK	De Ponti and Tonini, "Irritable Bowel Syndrome," <u>Drugs</u> , 2001, 61(3):317-332
SH	AL	Eddahibi and Adnot, "Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis," <u>Respir. Res.</u> , 2002, 3:9 (4 pgs.)
SH	AM	Goodnick and Goldstein, "Selective serotonin reuptake inhibitors in affective disorders - I. Basic pharmacology," <u>J. Psychopharmacology</u> , 1998, 12(3):S5-S20
SH	AN	Heils et al., "Allelic Variation of Human Serotonin Transporter Gene Expression," <u>J. Neurochem.</u> , 1996, 66:2621-2624
SH	AO	Horschitz et al., "Down-regulation of the rat serotonin transporter upon exposure to a selective serotonin reuptake inhibitor," <u>NeuroReport</u> , 2001, 12:2181-2184
SH	AP	Houghton et al., "Alosetron, a 5-HT ₃ receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers," <u>Aliment Pharmacol. Ther.</u> , 2000, 14:775-782
SH	AQ	Manor et al., "Family-Based Association Study of the Serotonin Transporter Promoter Region Polymorphism (5-HTTLPR) in Attention Deficit Hyperactivity Disorder," <u>Am. J. Med. Genet.</u> , 2001, 105:91-95
SH	AR	Mundo et al., "The Role of Serotonin Transporter Protein Gene in Antidepressant-Induced Mania in Bipolar Disorder," <u>Arch. Gen. Psychiatry</u> , 2001, 58:539-544

Examiner Signature <i>[Signature]</i>	Date Considered <i>August 22, 2002</i>
--	---


EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-355001	Application No. 10/058,630
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Michael L. Camilleri et al	
		Filing Date January 28, 2002	Group Art Unit 1645

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
SH	AS	Nutt et al., "Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders," <u>Eur. Neuropsychopharmacol.</u> , 1999, 9(Suppl. 3):S81-S86
SH	AT	Prior and Read, "Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT ₃ -receptor antagonist, in patients with irritable bowel syndrome," <u>Aliment Pharmacol. Ther.</u> , 1993, 7:175-180
SH	AU	Reist et al., "Serotonin Transporter Promoter Polymorphism Is Associated With Attenuated Prolactin Response to Fenfluramine," <u>Am. J. Med. Genet.</u> , 2001, 105:363-368
SH	AV	Samochowiec et al., "Polymorphisms in the Dopamine, Serotonin, and Norepinephrine Transporter Genes and Their Relationship to Temperamental Dimensions Measured by the Temperament and Character Inventory in Healthy Volunteers," <u>Neuropsychobiology</u> , 2001, 43:248-253
SH	AW	Seeger et al., "Functional polymorphism within the promoter of the serotonin transporter gene is associated with severe hyperkinetic disorders," <u>Mol. Psychiatry</u> , 2001, 6:235-238
SH	AX	Steadman et al., "Selective 5-Hydroxytryptamine Type 3 Receptor Antagonism With Ondansetron as Treatment for Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study," <u>Mayo Clin. Proc.</u> , 1992, 67:732-738
SH	AY	Stivland et al., "Scintigraphic Measurement of Regional Gut Transit in Idiopathic Constipation," <u>Gastroenterology</u> , 1991, 101:107-115
SH	AZ	Thumshirn et al., "Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome," <u>Aliment Pharmacol. Ther.</u> , 2000, 14:869-878
SH	AAA	Twitchell et al., "Serotonin Transporter Promoter Polymorphism Genotype Is Associated With Behavioral Disinhibition and Negative Affect in Children of Alcoholics," <u>Alcohol. Clin. Exp. Res.</u> , 2001, 25(7):953-959
SH	ABB	Vassallo et al., "Transit Through the Proximal Colon Influences Stool Weight in the Irritable Bowel Syndrome," <u>Gastroenterology</u> , 1992, 102:102-108
SH	ACC	von der Ohe et al., "Motor Dysfunction of the Small Bowel and Colon in Patients With the Carcinoid Syndrome and Diarrhea," <u>N. Engl. J. Med.</u> , 1993, 329:1073-1078
SH	ADD	Weizman and Weizman, "Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse," <u>Pharmacogenomics</u> , 2000, 1(3):335-341
SH	AEE	Wolfe et al., "Tolerability and Safety of Alosetron During Long-Term Administration in Female and Male Irritable Bowel Syndrome Patients," <u>Am J. Gastroenterol.</u> , 2001, 96(3):803-811
SH	AFF	Yirmiya et al. "Evidence for an Association With the Serotonin Transporter Promoter Region Polymorphism and Autism," <u>Am. J. Med. Genet.</u> , 2001, 105:381-386

Examiner Signature 	Date Considered August 22, 2002
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	